JP2011510049A - 包材により結合する経口医薬の組み合わせ - Google Patents
包材により結合する経口医薬の組み合わせ Download PDFInfo
- Publication number
- JP2011510049A JP2011510049A JP2010543522A JP2010543522A JP2011510049A JP 2011510049 A JP2011510049 A JP 2011510049A JP 2010543522 A JP2010543522 A JP 2010543522A JP 2010543522 A JP2010543522 A JP 2010543522A JP 2011510049 A JP2011510049 A JP 2011510049A
- Authority
- JP
- Japan
- Prior art keywords
- medicament
- dosage form
- pharmaceutical dosage
- form according
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000005022 packaging material Substances 0.000 title claims description 18
- 239000003814 drug Substances 0.000 claims abstract description 231
- 239000002552 dosage form Substances 0.000 claims abstract description 125
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims abstract description 33
- 239000005541 ACE inhibitor Substances 0.000 claims abstract description 30
- 230000000968 intestinal effect Effects 0.000 claims abstract description 27
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims abstract description 24
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000002876 beta blocker Substances 0.000 claims abstract description 18
- 229940097320 beta blocking agent Drugs 0.000 claims abstract description 18
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims abstract description 14
- 229940123208 Biguanide Drugs 0.000 claims abstract description 12
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims abstract description 11
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract description 11
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims abstract description 11
- 239000000935 antidepressant agent Substances 0.000 claims abstract description 11
- 229940005513 antidepressants Drugs 0.000 claims abstract description 11
- 229940049706 benzodiazepine Drugs 0.000 claims abstract description 11
- 239000000480 calcium channel blocker Substances 0.000 claims abstract description 11
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims abstract description 11
- 239000003158 myorelaxant agent Substances 0.000 claims abstract description 11
- 239000011591 potassium Substances 0.000 claims abstract description 11
- 229960003975 potassium Drugs 0.000 claims abstract description 11
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 11
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 11
- 229960003022 amoxicillin Drugs 0.000 claims abstract description 10
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 10
- 229960002626 clarithromycin Drugs 0.000 claims abstract description 10
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims abstract description 10
- 229960003009 clopidogrel Drugs 0.000 claims abstract description 10
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960002256 spironolactone Drugs 0.000 claims abstract description 10
- 229960003712 propranolol Drugs 0.000 claims abstract description 9
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims abstract description 9
- 229940126409 proton pump inhibitor Drugs 0.000 claims abstract description 8
- 150000004283 biguanides Chemical class 0.000 claims abstract description 7
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims abstract description 6
- 239000000612 proton pump inhibitor Substances 0.000 claims abstract description 6
- 238000009463 water soluble packaging Methods 0.000 claims abstract description 6
- 150000001557 benzodiazepines Chemical class 0.000 claims abstract description 5
- -1 corticoids Substances 0.000 claims abstract description 5
- 238000001727 in vivo Methods 0.000 claims abstract description 4
- 229940035363 muscle relaxants Drugs 0.000 claims abstract description 4
- 239000003826 tablet Substances 0.000 claims description 50
- 229940079593 drug Drugs 0.000 claims description 40
- 239000000463 material Substances 0.000 claims description 28
- 239000011159 matrix material Substances 0.000 claims description 20
- 238000000926 separation method Methods 0.000 claims description 19
- 230000002265 prevention Effects 0.000 claims description 16
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 13
- 208000037849 arterial hypertension Diseases 0.000 claims description 12
- 239000007888 film coating Substances 0.000 claims description 11
- 238000009501 film coating Methods 0.000 claims description 11
- 239000007903 gelatin capsule Substances 0.000 claims description 11
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 10
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 10
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 8
- 239000003470 adrenal cortex hormone Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 238000004806 packaging method and process Methods 0.000 claims description 8
- 230000001430 anti-depressive effect Effects 0.000 claims description 7
- 230000003902 lesion Effects 0.000 claims description 7
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 7
- 239000007901 soft capsule Substances 0.000 claims description 7
- 210000002784 stomach Anatomy 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims description 6
- 108010061435 Enalapril Proteins 0.000 claims description 6
- 235000007164 Oryza sativa Nutrition 0.000 claims description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 6
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 6
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 6
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 6
- 229920001577 copolymer Polymers 0.000 claims description 6
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 6
- 229960002965 pravastatin Drugs 0.000 claims description 6
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 6
- 235000009566 rice Nutrition 0.000 claims description 6
- 229960002855 simvastatin Drugs 0.000 claims description 6
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 5
- 229960000830 captopril Drugs 0.000 claims description 5
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 5
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims description 5
- 229960000873 enalapril Drugs 0.000 claims description 5
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 5
- 229920001610 polycaprolactone Polymers 0.000 claims description 5
- 239000004632 polycaprolactone Substances 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 claims description 4
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 claims description 4
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 claims description 4
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 4
- 208000008035 Back Pain Diseases 0.000 claims description 4
- 206010004016 Bacterial diarrhoea Diseases 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 241000195493 Cryptophyta Species 0.000 claims description 4
- 208000020401 Depressive disease Diseases 0.000 claims description 4
- 208000005189 Embolism Diseases 0.000 claims description 4
- 206010016654 Fibrosis Diseases 0.000 claims description 4
- 206010017886 Gastroduodenal ulcer Diseases 0.000 claims description 4
- 241000590002 Helicobacter pylori Species 0.000 claims description 4
- 208000019025 Hypokalemia Diseases 0.000 claims description 4
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 4
- 206010061216 Infarction Diseases 0.000 claims description 4
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 4
- 208000008469 Peptic Ulcer Diseases 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 4
- 208000001435 Thromboembolism Diseases 0.000 claims description 4
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 claims description 4
- 229960002122 acebutolol Drugs 0.000 claims description 4
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 claims description 4
- 238000002399 angioplasty Methods 0.000 claims description 4
- 229960002274 atenolol Drugs 0.000 claims description 4
- 239000012620 biological material Substances 0.000 claims description 4
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical group CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 claims description 4
- 229960002781 bisoprolol Drugs 0.000 claims description 4
- 230000007882 cirrhosis Effects 0.000 claims description 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 4
- 229960001259 diclofenac Drugs 0.000 claims description 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 4
- 230000008029 eradication Effects 0.000 claims description 4
- 229960002490 fosinopril Drugs 0.000 claims description 4
- 231100000029 gastro-duodenal ulcer Toxicity 0.000 claims description 4
- 230000001631 hypertensive effect Effects 0.000 claims description 4
- 229960001680 ibuprofen Drugs 0.000 claims description 4
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 4
- 229960000991 ketoprofen Drugs 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical group C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 claims description 4
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical group CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 4
- 229960002009 naproxen Drugs 0.000 claims description 4
- 229960000381 omeprazole Drugs 0.000 claims description 4
- 208000024896 potassium deficiency disease Diseases 0.000 claims description 4
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims description 4
- 229960003401 ramipril Drugs 0.000 claims description 4
- 238000011125 single therapy Methods 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims description 4
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 3
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 claims description 3
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 claims description 3
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 claims description 3
- 229960004538 alprazolam Drugs 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- 229960004195 carvedilol Drugs 0.000 claims description 3
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 229960004606 clomipramine Drugs 0.000 claims description 3
- 210000002249 digestive system Anatomy 0.000 claims description 3
- 238000001839 endoscopy Methods 0.000 claims description 3
- 229960004770 esomeprazole Drugs 0.000 claims description 3
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 claims description 3
- 229960003580 felodipine Drugs 0.000 claims description 3
- 229960002464 fluoxetine Drugs 0.000 claims description 3
- 229960000346 gliclazide Drugs 0.000 claims description 3
- 229960003174 lansoprazole Drugs 0.000 claims description 3
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims description 3
- 229960001571 loperamide Drugs 0.000 claims description 3
- 229960003105 metformin Drugs 0.000 claims description 3
- 229960001783 nicardipine Drugs 0.000 claims description 3
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical group COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 3
- 229960001597 nifedipine Drugs 0.000 claims description 3
- 229960004688 venlafaxine Drugs 0.000 claims description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 2
- 208000008930 Low Back Pain Diseases 0.000 claims description 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- VDTNNGKXZGSZIP-UHFFFAOYSA-N carbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 VDTNNGKXZGSZIP-UHFFFAOYSA-N 0.000 claims description 2
- 229960003362 carbutamide Drugs 0.000 claims description 2
- 238000005538 encapsulation Methods 0.000 claims description 2
- 229960004580 glibenclamide Drugs 0.000 claims description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 2
- 229960005205 prednisolone Drugs 0.000 claims description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 2
- 229960004618 prednisone Drugs 0.000 claims description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims 2
- YJYRIVVGIRCAHD-UHFFFAOYSA-N 1-bromoazepane Chemical group BrN1CCCCCC1 YJYRIVVGIRCAHD-UHFFFAOYSA-N 0.000 claims 1
- 240000007594 Oryza sativa Species 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 description 19
- 238000000034 method Methods 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 238000007789 sealing Methods 0.000 description 7
- 108010010803 Gelatin Proteins 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 241000209094 Oryza Species 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000007941 film coated tablet Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 230000009747 swallowing Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 239000008118 PEG 6000 Substances 0.000 description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- VMDFASMUILANOL-WXXKFALUSA-N bisoprolol fumarate Chemical compound [H+].[H+].[O-]C(=O)\C=C\C([O-])=O.CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1.CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VMDFASMUILANOL-WXXKFALUSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229940125725 tranquilizer Drugs 0.000 description 2
- 239000003204 tranquilizing agent Substances 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- VMIYHDSEFNYJSL-UHFFFAOYSA-N Bromazepam Chemical compound C12=CC(Br)=CC=C2NC(=O)CN=C1C1=CC=CC=N1 VMIYHDSEFNYJSL-UHFFFAOYSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 229940092980 adalat Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940092229 aldactone Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229940025141 anafranil Drugs 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229960002729 bromazepam Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940098766 effexor Drugs 0.000 description 1
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003168 generic drug Substances 0.000 description 1
- 229940095884 glucophage Drugs 0.000 description 1
- 229940095970 imodium Drugs 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940064748 medrol Drugs 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229940090008 naprosyn Drugs 0.000 description 1
- AIKVCUNQWYTVTO-UHFFFAOYSA-N nicardipine hydrochloride Chemical compound Cl.COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 AIKVCUNQWYTVTO-UHFFFAOYSA-N 0.000 description 1
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229940020573 plavix Drugs 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000012254 powdered material Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940035613 prozac Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 229940063674 voltaren Drugs 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
- 229940074158 xanax Drugs 0.000 description 1
- 229940072168 zocor Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/345—Nitrofurans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
−医薬は、市販の生薬形態である;
−医薬は、市販の生薬形態と同じ質及び量の組成物を有するが、幾何学的形態が異なる生薬形態である;
−少なくとも1つの市販の生薬形態と、少なくとも1つの類似の生薬形態との組み合わせ;
−包材、及び任意の分離シート又は壁が、規定の吸収部位(口、胃又は腸)のpH条件下で水溶性である物質から作製され;包材と異なり、分離シート又は壁は、必ずしも水溶性物質から作製される必要はなく;ただし、それは、包材の物質と適合する製薬材料から作製されなければならず;したがってそれは、同じ物質を使用することがより便利である;
−水溶性物質は、口(唾液)のpH、それはつまり、7〜8のオーダーのpHで水溶性である;
−水溶性物質は、胃のpH(非常に酸性のpH、一般的に約1)で水溶性である;
−水溶性物質は腸のpH、それはつまり、アルカリ性のpH(約8〜9)で水溶性である;
−組み合わせ医薬は、消化系の同じ腔で吸収されるか、異なる腔で吸収される;
−医薬剤型は、医薬の総重量が、1500mg以下、好ましくは1000mg以下、特に800、700又は600mg以下、特に500又は400mg以下である;
−医薬剤型は、口中で分解するもの以外の形態で、容易な嚥下に適する総容量を有する;
−組み合わせ医薬の生薬形態は同じ性質を有し;例えば、錠剤、被覆錠剤、ゼラチンカプセル又は軟カプセルから選択される;
−組み合わせ医薬の生薬形態は、異なる性質を有し、例えば2つの医薬の組み合わせの生薬形態:錠剤及び被覆錠剤、被覆錠剤及び軟カプセル、軟カプセル及びゼラチンカプセルがある;
−特に、少なくとも1つの医薬がカプセル又はゼラチンカプセルである場合、分離シート又は壁を省くことができ、この場合の物理的分離は、ゼラチンカプセル又はカプセルの壁によって確保される;
−組み合わせ医薬の重量は、実質的に同一であるか又は異なる;
−組み合わせ医薬の容量は、実質的に同一であるか又は異なる。
−これらは、分離シート及び包材のシートについて同じ性質である
−これらは、その端で封止される;
−これらは、規定の吸収部位のpHで水溶性である;
−これらは、口(唾液)のpH、それはつまり、7〜8のオーダーのpHで水溶性である;
−これらは、胃のpH(非常に酸性のpH、一般的に約1)で水溶性である;
−これらは、腸のpH、それはつまり、アルカリ性のpH(pHが約8〜9)で水溶性である;
−これらは、経口服用のための製薬材料から作製される;
−これらは、以下の物質の1つから形成されるか、それを含んでなる:生体材料、特に藻類由来もしくは藻類に基づく生体材料、セルロースポリマーもしくはコポリマー、ポリビニルアルコール、乳酸及び/もしくはグリコール酸誘導体、特にPLGA及びPLA、ポリカプロラクトン(PCL);
−当該物質は、最良な可能性ある手順で錠剤に包み込まれた錠剤の形状とするため、封止後、わずかに収縮してもよい;
−物質の厚みは、特に30〜300μmである。
端の封止の方法は、シートの物質に適合させる。
−これらが錠剤及び/又は被覆錠剤の場合、これらの各々は、形態の点で他方の面と相補的である面を有し、当該2つの面は、最終医薬剤型において互いに向かい合わせるようにし;これらの2つの面は、好ましくは平面又は実質的に平面である;
−錠剤及び/又は被覆錠剤の各々は、平面又は実質的に平面を有し、当該2つの面は、同じ形状である;
−前記2つの相補的面は、円形又は楕円形の形状である;
−前記最終医薬剤型は、球形又は伸びた球形(楕円形)を形成する;
−錠剤/被覆錠剤は、実質的に同一重量である;
−錠剤/被覆錠剤は、異なる重量である。
−非ステロイド系抗炎症薬(NSAIDS)、プロトンポンプ阻害剤(PPI)、ベータ−ブロッカー、スタチン、変換酵素阻害剤(CEI)、ビグアニド、筋弛緩剤、カルシウム阻害剤、コルチコイド、抗鬱剤、ベンゾジアゼピン、非アトロピン様腸管輸送遅延剤及び腸管抗細菌剤、並びに治療用分子である以下の、スピロノラクトン、アルダクトン、プロプラノロール、クラリスロマイシン、アモキシシリン、低用量アセチルサリチル酸(アスピリン)、カルベジロール、カリウム及びクロピドグレル。
−プロトンポンプ阻害剤(PPI)と組み合わせる非ステロイド系抗炎症薬(NSAIDS);
−スタチンと組み合わせるベータ−ブロッカー;
−スタチンと組み合わせる変換酵素阻害剤(CEI);
−ビグアニドと組み合わせるスタチン;
−筋弛緩剤と組み合わせるNSAID;
−CEIと組み合わせるカルシウム阻害剤;
−プロパノロールと組み合わせるスピロノラクトン;
−クラリスロマイシン及びアモキシシリンと組み合わせるPPI;
−クロピドグレルと組み合わせる、低用量アセチルサリチル酸(「幼児用」用量、これは、成人患者における血液流動化効果を有し、高血圧の問題を扱うため心臓学において一般に使用され;用量は75mg、例えば、75〜160mg用量である);
−CEI、スタチン及びベータ−ブロッカーと組み合わせる低用量アセチルサリチル酸;
−カリウムと組み合わせるコルチコイド(用量は、特に20〜100mgで変化する);
−(精神安定剤)ベンゾジアゼピンと組み合わせる抗鬱剤;
−腸抗細菌剤と組み合わせる非アトロピン様腸管輸送遅延剤。
−スタチンとして(クラスC10A1)、Elisor(登録商標)(プラバスタチン)、Zocor(登録商標)(シンバスタチン;
−プロトンポンプ阻害剤(クラスA2B2)として、Mopral(登録商標)(オメプラゾール);
−非ステロイド性抗炎症薬(M1A1)として、Naprosyne(登録商標)(ナプロキセン)、Nurofen(登録商標)(イブプロフェン)、Ketum(登録商標)(ケトプロフェン)及びVoltaren(登録商標)(ジクロフェナク);
−ベータ−ブロッカー(クラスC7A)として、Detensiel(登録商標)又はSoprol(登録商標)(ビソプロロール)、Tenormine(登録商標)(アトノロール)、Sectral(登録商標)(アセブトロール);Kredex(登録商標)(カルベジロール);
−変換酵素阻害剤(CEI、クラスC9A)として、Triatec(登録商標)(ラミプリル)、Lopril(登録商標)(カプトプリル)、Renitec(登録商標)(エナラプリル)、Fositec(登録商標)(ホシノプリル);
−ビグアニド(クラスA10B2)として、Glucophage(登録商標)(メトホルミン)及びDiamicron(登録商標)(グリクラジド);
−Solupred(登録商標)、Cortancyl(登録商標)、Medrol(登録商標)(コルチコイド);
−Kaleorid(登録商標)、Difuca(登録商標)(カルシウム塩);
−Zeclar(登録商標)又はNaxy(登録商標)(クラリスロマイシン)、Clamoxyl(登録商標)又はAgram(登録商標)(アモキシシリン);
−Aldactone(登録商標)50(スピロノラクトン)、Avlocardyl(登録商標)40(プロプラノロール);
−Adalat(登録商標)LD(ニフェジピン)、Flodil(登録商標)(フェロジピン)、Loxen(登録商標)(ニカルジピン);
−Imossel(登録商標)及びImodium(登録商標)(ロペラミド)、Ercefuryl(登録商標)(ニフロキソジド);
−Plavix(登録商標)(クロピドグレル);
−Anafranil(登録商標)(クロミプラミン)、Prozac(登録商標)(フルオキセチン)、Effexor(登録商標)(ベンラファキシン);
−Lexomil(登録商標)(ブロマゼパム)、Xanax(登録商標)(アルプラゾラム)(登録商標);
−又はそのジェネリック専売医薬。
Claims (47)
- 少なくとも2つの医薬を含有し、一方では、当該医薬を、リークプルーフ(leakproof)インビボ(in vivo)水溶性包材に集積し、他方では、組み合わせ医薬中の活性成分が互いに接触することができないように当該医薬を分離する、経口医薬剤型。
- 前記医薬が、市販の生薬形態(galenical form)及び/又は市販の生薬形態と同じ質及び量の組成物を有するが、幾何学的形態が異なる生薬形態である、請求項1に記載の医薬剤型。
- 前記医薬が、前記包材の内部に広がるシート又は壁により分離される、請求項1又は2に記載の医薬剤型。
- 前記包材、及び任意に、前記分離シート又は壁が、口のpH、胃のpH、又は腸のpHで水溶性である物質から作製される、請求項3に記載の医薬剤型。
- 2つ、3つ又は4つの医薬を含んでなる、請求項1〜4のいずれか1項に記載の医薬剤型。
- 前記医薬の総重量が1500mg以下、好ましくは1000mg以下、特に500mg以下である、請求項1〜5のいずれか1項に記載の医薬剤型。
- 前記組み合わせ医薬の生薬形態が、同じ性質又は異なる性質であり、且つ錠剤、被覆錠剤、ゼラチンカプセル及び軟カプセルから選択される、請求項1〜6のいずれか1項に記載の医薬剤型。
- 前記組み合わせ医薬、製薬材料の2つのシートから作製される包材、及び製薬材料から作製される少なくとも1つの分離シートを含んでなる、請求項1〜7のいずれか1項に記載の医薬剤型。
- 前記組み合わせ医薬、封止される軟カプセルにより形成される包材、及び製薬材料から作製される少なくとも1つの分離シートを含んでなる、請求項1〜7のいずれか1項に記載の医薬剤型。
- 前記組み合わせ医薬、各々が医薬を受ける少なくとも2つの区画を有するライスペーパーのマトリクス、及び覆いを形成する部分を含んでなる、請求項1〜7のいずれか1項に記載の医薬剤型。
- 封入マトリクスに包み込まれる前記組み合わせ医薬を含んでなる、請求項1〜7のいずれか1項に記載の医薬剤型。
- 前記包材が、以下の材料:生体材料、特に藻類由来もしくは藻類に基づく生体材料、セルロースポリマーもしくはコポリマー、ポリビニルアルコール、乳酸及び/もしくはグリコール酸誘導体、特にPLGA及びPLA、ポリカプロラクトン(PCL)のうちの1つから形成されるか、それを含んでなる、請求項1〜8のいずれか1項に記載の医薬剤型。
- 前記包材が、結合により集積される前記錠剤の外表面全体にわたり存在する、フィルム被覆である、請求項1〜6のいずれか1項に記載の医薬剤型。
- 前記異なる錠剤のフィルム被覆用のフィルム形成溶液が、同一であるか異なる、請求項13に記載の医薬剤型。
- 前記錠剤が、初めにフィルム被覆されてから結合するか、又は結合してからフィルム被覆される、請求項13又は14に記載の医薬剤型。
- 前記フィルム形成溶液が、ポリビニルアルコールとポリエチレングリコールのコポリマーを含むことができる、請求項13〜15のいずれか1項に記載の医薬剤型。
- 前記結合溶液とフィルム形成溶液が、同一であるか異なる、請求項13〜16のいずれか1項に記載の医薬剤型。
- 前記組み合わせ医薬が、同一であるか異なる消化系の腔(cavity)において吸収される、請求項1〜17のいずれか1項に記載の医薬剤型。
- 前記医薬の少なくとも1つのが、以下の治療分類:非ステロイド系抗炎症薬(NSAIDS)、プロトンポンプ阻害剤(PPI)、ベータ−ブロッカー、スタチン、変換酵素阻害剤(CEI)、ビグアニド、筋弛緩剤、カルシウム阻害剤、コルチコイド、抗鬱剤、ベンゾジアゼピン、非アトロピン様腸管輸送遅延剤及び腸管抗細菌剤、並びに以下の治療用分子:スピロノラクトン、プロプラノロール、クラリスロマイシン、アモキシシリン、低用量アセチルサリチル酸、カリウム及びクロピドグレルから選択される、請求項1〜18のいずれか1項に記載の経口医薬剤型。
- 以下の組み合わせ、
−プロトンポンプ阻害剤(PPI)と組み合わせる非ステロイド系抗炎症薬(NSAIDS);
−スタチンと組み合わせるベータ−ブロッカー;
−スタチンと組み合わせる変換酵素阻害剤(CEI);
−ビグアニドと組み合わせるスタチン;
−鎮痛剤及び/又は筋弛緩剤と組み合わせるNSAID;
−CEIと組み合わせるカルシウム阻害剤;
−プロプラノロールと組み合わせるスピロノラクトン;
−クラリスロマイシン及びアモキシシリンと組み合わせるPPI;
−CEI、スタチン及びベータ−ブロッカーと組み合わせる低用量アセチルサリチル酸;
−クロピドグレルと組み合わせる低用量アセチルサリチル酸;
−カリウムと組み合わせるコルチコイド;
−ベンゾジアゼピンと組み合わせる抗鬱剤;
−腸管抗細菌剤と組み合わせる非アトロピン様腸管輸送遅延剤;
を構成するために選択される医薬を含む、請求項19に記載の経口医薬剤型。 - 胃十二指腸病変の危険性のある患者の抗炎症治療のための、NSAIDを含んでなる医薬及びPPIを含んでなる医薬を含有する、請求項19又は20に記載の医薬剤型。
- 動脈性高血圧に罹患する患者における高コレステロール血症の治療のための、ベータ−ブロッカーを含んでなる医薬及びスタチンを含んでなる医薬を含有する、請求項19又は20に記載の医薬剤型。
- 潜在的対象における心臓血管疾患、特に高コレステロール血症に関連する動脈性高血圧である疾患の予防のための、CEIを含んでなる医薬及びスタチンを含んでなる医薬を含有する、請求項19又は20に記載の医薬剤型。
- 2型糖尿病に罹患する患者における心臓血管の危険の予防のための、ビグアニドを含んでなる医薬及びスタチンを含んでなる医薬を含有する、請求項19又は20に記載の医薬剤型。
- 前記ビグアニドが、メトホルミン、グリクラジド、カルブタミド及びグリベンクラミドから選択される、請求項24に記載の医薬剤型。
- 一般的な急性腰痛の治療のための、NSAIDを含んでなる医薬及び筋弛緩剤を含んでなる医薬を含有する、請求項19又は20に記載の医薬剤型。
- 前記筋弛緩剤がチオコルチコシドである、請求項26に記載の医薬剤型。
- 単回療法に対して耐性である動脈性高血圧の治療のための、カルシウム阻害剤を含んでなる医薬及びCEIを含んでなる医薬を含有する、請求項19又は20に記載の医薬剤型。
- 前記カルシウム阻害剤が、ニフェジピン、フェロジピン及びニカルジピンから選択される、請求項28に記載の医薬剤型。
- 肺性動脈性高血圧に罹患する患者における硬変の治療のための、スピロノラクトンを含んでなる医薬及びプロプラノロールを含んでなる医薬を含有する、請求項19又は20に記載の医薬剤型。
- 成人における胃十二指腸潰瘍疾患の場合、特に病変及び疾患の内視鏡検査による、細菌ヘリコバクター・ピロリ(Helicobacter pylori)の根絶治療のための、PPIを含んでなる医薬、クラリスロマイシンを含んでなる医薬、及びアモキシシリンを含んでなる医薬を含有する、請求項19又は20に記載の医薬剤型。
- 梗塞後の治療のための、低用量アセチルサリチル酸を含んでなる医薬、CEIを含んでなる医薬、スタチンを含んでなる医薬、及びベータ−ブロッカーを含んでなる医薬を含有する、請求項19又は20に記載の医薬剤型。
- 高血圧患者及び血管形成術を受けている患者における、血栓塞栓症の危険性の予防のための、低用量アセチルサリチル酸を含んでなる医薬及びクロピドグレルを含んでなる医薬を含有する、請求項19又は20に記載の医薬剤型。
- コルチコ療法(corticotherapy)による治療を必要とする患者における、低カリウム血症の予防のための、コルチコイドを含んでなる医薬及びカリウムを含んでなる医薬を含有する、請求項19又は20に記載の医薬剤型。
- カリウムがカリウム塩である、請求項34に記載の医薬剤型。
- 前記コルチコイドが、プレドニソロン及びプレドニゾンから選択される、請求項34に記載の医薬剤型。
- 鬱の治療のための、抗鬱剤を含んでなる医薬、ベンゾジアゼピンを含んでなる医薬を含有する、請求項19又は20に記載の医薬剤型。
- 腸管輸送の回復及び細菌性下痢の治療のための、非アトロピン様腸管輸送遅延剤を含んでなる医薬及び腸管抗細菌剤を含んでなる医薬を含有する、請求項19又は20に記載の医薬剤型。
- 前記非アトロピン様腸管輸送遅延剤がロペラミドである、請求項38に記載の医薬剤型。
- 前記抗細菌剤がニフロキサジドである、請求項38に記載の医薬剤型。
- 前記NSAIDが、ナプロキセン、ケトプロフェン、ジクロフェナク及びイブプロフェンから選択される、請求項19、20、21及び26のいずれか1項に記載の医薬剤型。
- 前記CEIが、ラミプリル、カプトプリル、エナラプリル及びホシノプリルから選択される、請求項19、20、23、28及び32のいずれか1項に記載の医薬剤型。
- 前記PPIが、オメプラゾール、エソメプラゾール及びランソプラゾールから選択される、請求項19、20、21及び31のいずれか1項に記載の医薬剤型。
- 前記スタチンが、プラバスタチン、シンバスタチンから選択される、請求項19、20、22、23、24、32及び33のいずれか1項に記載の医薬剤型。
- 前記ベータ−ブロッカーが、ビソプロロール、アテノロール、アセブトロール、カルベジロールから選択される、請求項19、20、22及び32のいずれか1項に記載の医薬剤型。
- 前記抗鬱剤が、三環式抗鬱剤、例えば、クロミプラミン、又は選択的セロトニン再取込み阻害剤、例えばフルオキセチン又はベンラファキシンである、請求項37に記載の医薬剤型。
- 前記ベンゾジアゼピンが、ブロマゼパン及びアルプラゾラムから選択される、請求項37に記載の医薬剤型。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US665108P | 2008-01-25 | 2008-01-25 | |
US665208P | 2008-01-25 | 2008-01-25 | |
FR0850460A FR2926723B1 (fr) | 2008-01-25 | 2008-01-25 | Associations pharmaceutiques orales. |
FR0850461A FR2926724B1 (fr) | 2008-01-25 | 2008-01-25 | Nouvelle forme pharmaceutique orale. |
PCT/EP2009/050858 WO2009092819A1 (en) | 2008-01-25 | 2009-01-26 | Combination of oral medicaments bonded by a wrapping |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014223306A Division JP5986169B2 (ja) | 2008-01-25 | 2014-10-31 | 包材により結合する経口医薬の組み合わせ |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2011510049A true JP2011510049A (ja) | 2011-03-31 |
Family
ID=40456977
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010543522A Withdrawn JP2011510049A (ja) | 2008-01-25 | 2009-01-26 | 包材により結合する経口医薬の組み合わせ |
JP2014223306A Expired - Fee Related JP5986169B2 (ja) | 2008-01-25 | 2014-10-31 | 包材により結合する経口医薬の組み合わせ |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014223306A Expired - Fee Related JP5986169B2 (ja) | 2008-01-25 | 2014-10-31 | 包材により結合する経口医薬の組み合わせ |
Country Status (11)
Country | Link |
---|---|
US (2) | US20110027356A1 (ja) |
EP (1) | EP2249815B1 (ja) |
JP (2) | JP2011510049A (ja) |
CN (1) | CN101969933B (ja) |
AU (1) | AU2009207580B8 (ja) |
BR (1) | BRPI0907414A2 (ja) |
CA (1) | CA2713197C (ja) |
ES (1) | ES2817504T3 (ja) |
MX (1) | MX344778B (ja) |
RU (1) | RU2493832C2 (ja) |
WO (1) | WO2009092819A1 (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2900799A1 (fr) * | 2006-05-15 | 2007-11-16 | Lesaffre & Cie | Nouvel agent substitut du sel naci, son utilisation et produits en contenant |
EP2389173A1 (en) * | 2009-01-22 | 2011-11-30 | Sanofi | New combination of active ingredients containing a non steroidal anti inflammatory drug and a colchicoside derivative |
TWI463998B (zh) * | 2009-12-31 | 2014-12-11 | Synmosa Biopharma Corp | Amoxicillin and clomycin have a high absorption rate of pharmaceutical ingredients |
FR2962647B1 (fr) | 2010-07-19 | 2013-05-24 | Duo Ge | Dispositif et installation d'assemblage d'au moins deux capsules medicamenteuses par collage |
JP5599522B2 (ja) * | 2011-01-10 | 2014-10-01 | コチ・ウニヴェルシテシ | 表面開始光重合を介するpegヒドロゲルでの被包化疎水性および親水性エアロゲル |
WO2012173581A1 (en) * | 2011-03-21 | 2012-12-20 | Ak Kimya Ithalat-Ihracat Ve Sanayii A.S. | Thiocolchicoside, etodolac and famotidine combinations |
CN102657634B (zh) * | 2012-05-09 | 2013-06-12 | 张奎昌 | 一种硝呋酚酰肼微囊粉及其生产方法 |
ITMI20121782A1 (it) * | 2012-10-22 | 2014-04-23 | Epifarma Srl | Composizione iniettabile stabile contenente diclofenac e tiocolchicoside |
JP2020018326A (ja) * | 2016-10-17 | 2020-02-06 | 株式会社菊水製作所 | 製剤の製造方法及び製造装置 |
JP2020507621A (ja) * | 2017-01-23 | 2020-03-12 | ドン ファ ファーマシューティカル カンパニー リミテッド | HMG−CoA還元酵素阻害剤およびクロピドグレルを含む複合製剤 |
CN108451933A (zh) * | 2017-02-16 | 2018-08-28 | 人福普克药业(武汉)有限公司 | Nsaid缓释纳米颗粒及其制备方法 |
CN110698656A (zh) * | 2019-10-12 | 2020-01-17 | 西安交通大学 | 一种低温熔融药物缓释医用高分子材料合成方法及应用 |
US20220087933A1 (en) * | 2019-11-26 | 2022-03-24 | Shauna Angelidis | Pet Treat Pocket |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6211135U (ja) * | 1985-07-02 | 1987-01-23 | ||
JPH11501948A (ja) * | 1996-01-08 | 1999-02-16 | アストラ・アクチエボラーグ | プロトンポンプ阻害剤およびnsaidからなる経口用医薬剤形 |
JP2003521287A (ja) * | 1999-07-09 | 2003-07-15 | バイオプログレス・テクノロジー・インターナショナル・インコーポレイテッド | デリバリーカプセルにおける、およびデリバリーカプセルに関連する改良 |
JP2004513080A (ja) * | 2000-08-17 | 2004-04-30 | マシーンズ インダストリエールズ エタブリッスメンツ | 摂取可能な容器 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH552510A (fr) * | 1972-02-14 | 1974-08-15 | Aspro Nicholas Ltd | Plaque contenant un ou plusieurs comprimes rectangulaires. |
CH624846A5 (en) * | 1975-12-15 | 1981-08-31 | Hoffmann La Roche | Solid pharmaceutical unit dose form and process and apparatus for producing it |
US4198390A (en) * | 1979-01-31 | 1980-04-15 | Rider Joseph A | Simethicone antacid tablet |
FR2524311A1 (fr) * | 1982-04-05 | 1983-10-07 | Azalbert Gilles | Gelule compartimentee aux fins d'ingestions simultanees a effets differes |
US4738724A (en) * | 1983-11-04 | 1988-04-19 | Warner-Lambert Company | Method for forming pharmaceutical capsules from starch compositions |
JPH069375A (ja) * | 1992-04-10 | 1994-01-18 | Takeda Chem Ind Ltd | 分割可能な連結錠剤 |
TW483763B (en) * | 1994-09-02 | 2002-04-21 | Astra Ab | Pharmaceutical composition comprising of ramipril and dihydropyridine compound |
DE4446468A1 (de) * | 1994-12-23 | 1996-06-27 | Basf Ag | Verfahren zur Herstellung von umhüllten Tabletten |
SE9500422D0 (sv) * | 1995-02-06 | 1995-02-06 | Astra Ab | New oral pharmaceutical dosage forms |
US6077539A (en) * | 1996-11-12 | 2000-06-20 | Pozen, Inc. | Treatment of migraine headache |
NZ516733A (en) * | 1999-07-30 | 2004-03-26 | Smithkline Beecham Plc | Pharmaceutical formulations for oral dosing that are dosage forms comprising two or more connected sub-units |
AU780424B2 (en) * | 1999-11-17 | 2005-03-17 | Reckitt Benckiser (Uk) Limited | Injection-moulded water-soluble container |
US6254888B1 (en) * | 2000-01-28 | 2001-07-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for coating pharmaceutical dosage forms |
US7125561B2 (en) * | 2001-05-22 | 2006-10-24 | Euro-Celtique S.A. | Compartmentalized dosage form |
US6669955B2 (en) * | 2001-08-28 | 2003-12-30 | Longwood Pharmaceutical Research, Inc. | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
MY142179A (en) * | 2002-07-25 | 2010-10-15 | Glaxo Group Ltd | Multicomponent pharmaceutical dosage form |
SI21402A (sl) * | 2003-02-12 | 2004-08-31 | LEK farmacevtska dru�ba d.d. | Obloženi delci in farmacevtske oblike |
US20050053648A1 (en) * | 2003-09-08 | 2005-03-10 | Chalmers Anne Marie | Medication delivery device |
TWI388345B (zh) * | 2005-06-27 | 2013-03-11 | Sankyo Co | 用於高血壓之預防或治療之包含血管緊張素ⅱ受體拮抗劑及鈣通道阻斷劑之固體劑型 |
-
2009
- 2009-01-26 RU RU2010135514/15A patent/RU2493832C2/ru active IP Right Revival
- 2009-01-26 MX MX2010008071A patent/MX344778B/es active IP Right Grant
- 2009-01-26 EP EP09704297.2A patent/EP2249815B1/en active Active
- 2009-01-26 AU AU2009207580A patent/AU2009207580B8/en not_active Ceased
- 2009-01-26 BR BRPI0907414-7A patent/BRPI0907414A2/pt not_active Application Discontinuation
- 2009-01-26 US US12/864,397 patent/US20110027356A1/en not_active Abandoned
- 2009-01-26 WO PCT/EP2009/050858 patent/WO2009092819A1/en active Application Filing
- 2009-01-26 CA CA2713197A patent/CA2713197C/en active Active
- 2009-01-26 ES ES09704297T patent/ES2817504T3/es active Active
- 2009-01-26 CN CN200980106576.3A patent/CN101969933B/zh active Active
- 2009-01-26 JP JP2010543522A patent/JP2011510049A/ja not_active Withdrawn
-
2014
- 2014-10-31 JP JP2014223306A patent/JP5986169B2/ja not_active Expired - Fee Related
-
2015
- 2015-04-03 US US14/678,464 patent/US20160000715A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6211135U (ja) * | 1985-07-02 | 1987-01-23 | ||
JPH11501948A (ja) * | 1996-01-08 | 1999-02-16 | アストラ・アクチエボラーグ | プロトンポンプ阻害剤およびnsaidからなる経口用医薬剤形 |
JP2003521287A (ja) * | 1999-07-09 | 2003-07-15 | バイオプログレス・テクノロジー・インターナショナル・インコーポレイテッド | デリバリーカプセルにおける、およびデリバリーカプセルに関連する改良 |
JP2004513080A (ja) * | 2000-08-17 | 2004-04-30 | マシーンズ インダストリエールズ エタブリッスメンツ | 摂取可能な容器 |
Also Published As
Publication number | Publication date |
---|---|
US20110027356A1 (en) | 2011-02-03 |
ES2817504T3 (es) | 2021-04-07 |
EP2249815A1 (en) | 2010-11-17 |
AU2009207580A1 (en) | 2009-07-30 |
JP5986169B2 (ja) | 2016-09-06 |
MX344778B (es) | 2017-01-06 |
CA2713197C (en) | 2016-10-04 |
CN101969933A (zh) | 2011-02-09 |
AU2009207580B8 (en) | 2014-06-12 |
BRPI0907414A2 (pt) | 2019-02-26 |
RU2493832C2 (ru) | 2013-09-27 |
US20160000715A1 (en) | 2016-01-07 |
MX2010008071A (es) | 2010-12-21 |
RU2010135514A (ru) | 2012-02-27 |
JP2015042672A (ja) | 2015-03-05 |
WO2009092819A1 (en) | 2009-07-30 |
AU2009207580A8 (en) | 2014-06-12 |
CN101969933B (zh) | 2016-03-30 |
EP2249815B1 (en) | 2020-06-24 |
AU2009207580B2 (en) | 2014-05-29 |
CA2713197A1 (en) | 2009-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5986169B2 (ja) | 包材により結合する経口医薬の組み合わせ | |
JP6349087B2 (ja) | 方法およびソフトジェルカプセル | |
US6941948B2 (en) | Medicament storage and delivery devices | |
AU2005306283C1 (en) | Pharmaceutical product | |
WO2007047371A2 (en) | Pharmaceutical packaging of an oral dosage combination | |
US20110061345A1 (en) | Solid and semi-solid dosage forms and systems and methods for forming and packaging thereof | |
WO2007021032A1 (ja) | 正確な用量分割機能を有する製剤 | |
FR2926723A1 (fr) | Associations pharmaceutiques orales. | |
FR2926724A1 (fr) | Nouvelle forme pharmaceutique orale. | |
Fulzele et al. | Drug Delivery: Fast Dissolve Systems | |
WO2007093021A1 (en) | Package, or drug kit, or drug smooth administration presentation for the treatment of hypertension, angina and others kinds of cardiovascular diseases. | |
MX2008004895A (en) | Pharmaceutical packaging of an oral dosage combination | |
WO2007093020A1 (en) | Package, or drug kit, or drug smooth administration presentation for the treatment of hypertension, cardiovascular diseases and decrease platelet aggregation. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120124 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130718 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130723 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131022 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131029 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131216 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140701 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141031 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20141104 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20141125 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20141210 |